Competition Results

Project title: Improving our understanding of pain mechanisms in people with knee osteoarthritis

Annual commitment:
Year 1: $124,989
Year 2: $124,950
Year 3: $125,000

Project summary: What causes pain to worsen for people with knee osteoarthritis?

One of the most common and disabling health issues is the pain and limitations caused by osteoarthritis (OA). The knee is a joint that is commonly affected by OA. Identifying the various causes of OA pain is a significant challenge. Dr. Lisa Carlesso will use existing databases of people with knee OA to compare and confirm what causes the pain and identify which patients will get worse. Dr. Carlesso will also study a yoga-based program to determine whether it is better than traditional exercise and education for relieving pain. The results of these studies have the potential to improve pain management and quality of life for people with knee OA.

Project title:  Elucidating the role of tryptase proteolytic processing of lubricin in osteoarthritis 

Annual commitment: 
Year 1: $125,000 
Year 2: $125,000 
Year 3: $125,000 

Project summary: Comprehensive solutions to address complex problems: Increasing joint lubrication and patient comfort by reducing cartilage degeneration in osteoarthritis 

It is estimated that up to 5 million Canadians may have osteoarthritis (OA). There is no cure for OA, highlighting an urgent need to better understand the disease and develop new treatments. Current approaches to treat OA focus on a trial-and-error approach, leading to delays in pain control, acceleration of joint and cartilage damage, and disability. Although the development of OA can be associated with previous joint injury, the causes of OA are complex. Dr. Antoine Dufour will investigate how the activation of certain substances that cause persistent pain and swelling can also promote loss of joint lubrication and cartilage destruction. He will explore a new way to increase joint lubrication by decreasing cartilage destruction for people with OA. 

Project title: A complex transition: Examining the impact of rheumatic disease on the multifaceted experience of entering adulthood

Annual commitment:
Year 1: $124,910
Year 2: $123,247
Year 3: $124,982

Project summary: Exploring health, social and career challenges for young adults with rheumatic disease

Entering adulthood can be challenging for young people, and their experiences during this phase can shape their future. But what about young people entering adulthood with a rheumatic disease? How does having a chronic disease affect access to healthcare, the ability to graduate from school and enter the workforce, move away from home, and socialize? Dr. Arif Jetha will answer these questions through a review of current research, focus groups, and a survey of young people with and without rheumatic disease. Findings will highlight the unique challenges confronting young people with rheumatic disease and create opportunities for tailored strategies that promote health, quality of life and employment.

Project title: Joints and sex – Re-envisioning osteoarthritis

Annual commitment:
Year 1: $124,998
Year 2: $124,999
Year 3: $125,000

Project summary: Rethinking how we view osteoarthritis - multiple joints and sex

Osteoarthritis (OA) is a major cause of pain and disability and effective treatment remains a big challenge. Even though many people with OA have multiple joints affected, most research and care focuses only on specific joints. As well, males and females with OA pain are treated similarly. Dr. Anthony Perruccio’s work shows that specific inflammatory markers in the blood relate to the number of joints involved in the disease – however in one way for females and another way for males. This has important implications as the treatment of OA pain may need to be tailored by sex, and whether single or multiple joints are affected. In this study, Dr. Perruccio will investigate whether the patterns of inflammatory markers in joints is important, and if there are important sex differences that could lead to improvements in how OA pain is treated.

Project title:  Adapting REhabilitation Delivery for Maximum Impact at Home (ReDI@Home) 

Annual commitment: 
Year 1: $100,000 
Year 2: $140,000 
Year 3: $120,000 

Project summary: ReDI@Home - Taking care of your arthritis at home 

People who live in rural areas and have hip or knee pain can find it challenging to access rehabilitation services in their community. Living with joint pain can lead to difficulty performing activities of daily living and being physically active which in turn can reduce enjoyment of life or cause other health conditions. Dr. Lauren Beaupre will use new smart phone technology that allows physiotherapists in urban centres to treat rural residents in their own homes. Over eight weeks, therapists will meet virtually with patients and see how well they move. They will give patients exercises to do at home each week and watch to make sure they do them correctly. Patients can also talk to the therapists to discuss pain management and how to remain active. If this new technology is successful, other patients who may not be able to access appropriate healthcare in their community will receive effective virtual care at home. 

Project title:  Understanding the role of Lipocalin Prostaglandin D Synthase in osteoarthritis 

Annual commitment: 
Year 1: $100,000 
Year 2: $140,000 
Year 3: $120,000 

Project summary: L-PGDS: A new therapeutic target in osteoarthritis 

Osteoarthritis (OA) is the most common form of arthritis and a leading cause of disability in Canada. It has a significant impact on quality of life and places a tremendous burden on the healthcare system. Since there is no cure for OA, there is a need to better understand how it progresses to develop more effective treatments. Dr. Hassan Fahmi will study the molecular mechanisms underlying the development of OA. Previous studies suggest that an enzyme, lipocalin-type prostaglandin D synthase (L-PGDS), may have protective properties against OA. Dr. Fahmi will study L-PGDS and its role in OA which may lead to better treatments and quality of life for people with OA. 

Project title: Targeted knee osteoarthritis care for adults with severe obesity: The Prevention Of MusclE Loss in Osteoarthritis (P.O.M.E.L.O.) feasibility and pilot randomized trial

Annual commitment:
Year 1: $100,000
Year 2: $140,000
Year 3: $120,000

Project summary: Developing personalized care for advanced knee arthritis in adults with obesity

The best way to treat advanced knee osteoarthritis (OA) in Canadians with obesity is unknown. These patients are less likely to be referred for surgical arthritis treatment due to a higher risk of infection after surgery. They are often told to lose weight even though it is uncertain if weight loss is beneficial for advanced arthritis. Further, weight loss could increase the risk for muscle loss and development of sarcopenic obesity (a condition of low muscle and low strength that negatively impacts mobility and quality of life). There may be better approaches to manage advanced knee OA for these patients. Dr. Carla Prado will determine if a program tailored to meet the needs of Canadians with obesity and knee OA is feasible to patients and improves their muscle mass and physical function. This work will support the future development of more effective non-surgical treatment approaches for this underserved patient group.

Project title: Senolytic drugs to treat back pain from spine OA

Annual commitment:
Year 1: $100,000
Year 2: $140,000
Year 3: $120,000

Project summary: Disease modifying drugs for spine osteoarthritis

World-wide, low back pain due to osteoarthritis (OA) of the spine is the single largest cause of years lived with disability. Current treatments like physiotherapy or medication may reduce pain and slow degeneration of the intervertebral discs in the spine but do not stop the progression of the disease. Senolytic therapy destroys senescent (or arrested) cells that cause inflammation in old tissues, leading to rejuvenation and slower progression of many age-related conditions. Dr. Lisbet Haglund will study two promising senolytic therapies, a natural compound, o-Vanillin, and an approved drug, RG-7112. This study may lead to the first disease modifying drugs for low back pain resulting from OA of the spine.

Project title: Rheumatoid arthritis in Canadian primary care settings: epidemiology, management of care and patient experience

Annual commitment:
Year 1: $99,974
Year 2: $139,938
Year 3: $119,740

Project summary: Rheumatoid arthritis in Canadian primary care settings

Family physicians play a key role in the management of rheumatoid arthritis (RA). They are often the patient’s first contact with the healthcare system. The management of RA across many provinces is not known. Using data from a Canadian national surveillance network that collects information from family physicians in the community, Dr. Allyson Jones will look at the number of people who are seen by family physicians for RA and the type of treatment they receive, both before they are diagnosed with RA and afterward. Dr. Jones will interview people with RA to understand their perspectives on managing RA and navigating the healthcare system. She will also interview family physicians and rheumatologists to learn about their experiences of diagnosing and supporting patients with RA The short-term impact will be a national description of healthcare provided by physicians. The long-term impact will identify any gaps in primary care and provide direction to address these gaps.

Project title: The effectiveness of medial pivot knee arthroplasty implants at improving gait and clinical outcomes in patients with knee osteoarthritis: A randomized controlled trial

Annual commitment:
Year 1: $98,723
Year 2: $135,248
Year 3: $120,000

Project summary: How different knee replacement designs influence knee movement during walking

Over 67,000 knee replacements are performed annually in Canada for knee arthritis and 20% of patients remain unsatisfied after surgery. New implants have been designed, called medial pivot implants, which claim to more closely mimic normal knee movements. There has been limited testing of these implants, so their effectiveness and safety are not clear. Dr. Shawn Robbins will compare knee movement before and after surgery for walking and stair climbing, pain, and physical function between patients who had medial pivot or traditional knee replacement implants. A better understanding of the most effective knee implants will help to maximize patient outcomes, minimize negative side effects, and decrease demands on the healthcare system.

Project title: PERSON-JIA: The Personalized Estimates of Response and Severity Outcomes in newly-diagnosed Juvenile Idiopathic Arthritis trial

Annual commitment:
Year 1: $100,000
Year 2: $129,932
Year 3: $112,680

Project summary: A truly personalized approach to treatment decisions for children with arthritis

When arthritis strikes a child, families face tough questions. Will their child suffer? Will they outgrow arthritis? Will they respond to treatment? Will there be side effects? The answers to these questions are crucial to choosing the best treatment for their child. Using information provided by thousands of families, Dr. Lori Tucker has developed a way of providing answers to these questions that are specific for the child and accessible on the doctor’s smartphone. The answers are generated automatically based on the child’s circumstances using “personalized prediction algorithms” and presented in an app. In this study, Dr. Tucker will test whether doctors who use the app to guide discussions with family on treatment choices for childhood arthritis, see better treatment response than doctors who do not. This work may result in better disease control, greater family engagement and satisfaction with care, and better-tailored treatment.

Project title:  Modeling cognitive impairment in patients with systemic lupus erythematosus: Clinical phenotyping, predictive trajectory, and associated risk factors 

Annual commitment: 
Year 1: $100,000 
Year 2: $139,932 
Year 3: $119,987 

Project summary: Modeling differences in cognitive impairment in lupus  

Up to 33-43 per cent of people with systemic lupus erythematosus (SLE) experience cognitive impairment (CI). CI includes a decline in memory, thinking speed, attention, and planning, and reduces quality of life. There is a need to identify clinical subtypes of CI in SLE and in those patients at high risk of developing impairment. Dr. Zahi Touma will determine subtypes of CI by using new data analysis techniques. Identifying patients with a high-risk of CI and those who are likely to have severe impairment over time will enhance the management of the disease and slow its progression.  

Project title: Identifying epidemiological, metabolomic, and genetic factors associated with non-responders to total joint replacement surgery in primary osteoarthritis patients

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Identifying factors to predict total joint replacement surgery success

Osteoarthritis (OA) is the most common type of arthritis, affecting more Canadians than all other forms of arthritis combined. Total joint replacement (TJR) is considered the most effective treatment for end-stage OA. However, as many as one third of patients see little to no improvement in pain and/or function after surgery. Identifying factors to predict which patients will have minimal response is imperative to save both patients and the healthcare system the stress of unsuccessful surgery. Under the supervision of Drs. Guangju Zhai and Edward Randell, Christie Costello will work to determine factors that are associated with non-responders to TJR from patient history, blood plasma biomarkers, genetic information, and markers of OA inflammation. The results of the study will raise awareness of who is a non-responder to TJR and offer insights to improve outcomes for both the surgery and quality of life of OA and TJR patients.

Project title: Investigation of the impact of secreted phospholipase A2-IIA on the intestinal microbiota during arthritis

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Bacteria in the intestine affect the development of rheumatoid arthritis

Every human shares its body with trillions of bacteria. While microbes in the intestines, which include bacteria, are widely known for their role in the digestive process, they also have a role in the regulation of the immune system. Alterations in the normal population of intestinal microbes have been observed in patients with autoimmune diseases, including rheumatoid arthritis (RA). Under the supervision of Dr. Eric Boilard, Etienne Doré is working to identify why these alterations occur and their contribution to the development of RA. A better understanding of the roles played by intestinal bacteria in this disease could help explain how arthritis develops and lead to the discovery of new therapeutic targets for the treatment of patients suffering from RA.

Project title: Investigating the role of CD22 in germinal centre B cell responses and autoimmune arthritis

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500

Project summary: Understanding the role of the CD22 protein in autoimmune arthritis development

It is estimated that over 1 million Canadians have inflammatory arthritis (IA). Most forms of IA are also autoimmune diseases, where the immune system – the body’s defense system against infections and other invaders – mistakenly starts to attack the body’s own healthy tissues. Unfortunately, there is no cure for this type of arthritis and medications for symptoms are not always effective. Understanding how IA develops is crucial for developing better therapies. Jhon Enterina, under the supervision of Dr. Matthew Macauley, is focusing on how specialized type of cells called germinal centre (GC) B-cells are formed. In patients with IA, GC B-cells are present in inflamed joints, producing molecules, called autoantibodies, that attack cells in the joints. The researchers have found that a protein called CD22 is required for antibody production and deleting it on B-cells delays arthritis development in mice. Jhon Enterina’s research aims to create new insights in GC B-cell biology and identify new targets for the treatment of IA.

Project title: The role of FcyRIIA in neuropsychiatric lupus erythematosus

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: From head to toe, the hidden side of how systemic lupus erythematosus affects the brain

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the body’s immune system attacks and causes inflammation in its own tissues. People with SLE more frequently experience depression and anxiety, which can be due not only to chronic pain and psychological distress, but to the inflammation itself. Studies have shown that >90% of lupus patients have mood disorders, cognitive impairment (e.g. memory loss), migraines, and even psychosis. Under the supervision of Dr. Eric Boilard, Audrée Laroche will use a new mouse model and state-of-the-art microscopes to visualize cells in the brains of living mice who have lupus. They will also look at fluid from the brains of people with SLE to determine whether they contain molecules capable of causing inflammation. This research will lead to a better understanding of how neurologic and psychiatric symptoms develop in SLE, and how rheumatic disease affect the brain more broadly.

Project title: Monitoring and improving physical activity participation in pediatric rheumatic disease 

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Staying active with childhood arthritis

Children with arthritis are often less physically active than their healthy peers due to decreased physical functioning, fatigue, and pain. This perpetuates a cycle of deconditioning, limiting participation in activities. Under the supervision of Dr. Brian Feldman, Yvonne Lee will investigate ways to help children break out of this cycle. She plans to research methods to improve physical activity tolerance and regular activity through oral supplements, use of activity trackers, and physical activity counseling. If proven to be effective, these tools may become standard practices for managing childhood arthritis.

Project title: Evaluating senolytics as a treatment option in SPARC-null mice

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500

Project summary: Assessing potential new treatments for lower back pain

Intervertebral disc degeneration, the breakdown of the discs that separate the vertebrae or bones of the spine, is a major cause of back pain, and up to 85% of working people experience low backpain during their lifetime. Current treatments alleviate symptoms but not the progression of the disease, there is a great need for novel disease modifying drugs. Recently, Dr. Lisbet Haglund and her team demonstrated the beneficial effects of two types of senolytic therapies: natural compounds, curcumin and o-Vanillin, and an approved drug, RG-7112, to reduce disc degeneration and back pain. Senolytic therapy destroys senescent cells that create inflammation in old tissues, leading to rejuvenation and slower progression of many age-related conditions. Under the supervision of Dr. Haglund, Matthew Mannarino, is studying two of these senolytic therapies, RG-7112 and o-Vanillin. This project aims to develop new treatments to prevent disc degeneration and decrease back pain.

Project title: Investigating the serological changes that accompany the onset of symptoms in anti-nuclear antibody associated systemic autoimmune rheumatic diseases

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500

Project summary: Looking for blood changes to predict development of lupus and other systemic autoimmune rheumatic diseases

Systemic autoimmune rheumatic diseases (SARD), like lupus, are serious diseases that affect not only the joints but also many other organs, such as the kidneys, skin, and brain. Many people with these conditions already have permanent organ damage when they are diagnosed and unfortunately, there is no cure. Antinuclear antibodies (ANA) are proteins produced by the immune system that are a hallmark of SARD patients but are also found in healthy people who will never develop SARD. Currently, there is no test that differentiates healthy people with ANA from those who will become sick. Under the supervision of Dr. Joan Wither, Carolina Munoz-Grajales is searching for differences in ANA between people with and without symptoms, and for the alterations in the immune system that ultimately cause SARD. Discovering a blood test that helps to identify patients who are at high risk of developing SARD could lead to earlier treatment before organ damage occurs. 

Project title: Targeting PRohibitins for Early DetectIon and Cure of osteoarthiTis: "The PREDICT Study"

Annual commitment (plus 50/50 match):
Year1: $20,000
Year 2: $20,000
Year 3: $20,000

Project summary: New path to PREDICT osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis, affecting nearly five million Canadians (one in six), which is more than all other forms of arthritis combined. OA is a progressive disease of the joints that leads to breakdown of joint cartilage and the underlying bone. The diagnosis is made based on symptoms and physical examination. Currently, it is not possible to determine which patients have a greater risk of rapid progression of OA, but a better understanding of the role of biomarkers may close the gap between diagnosis and reaching an untreatable stage. Under the supervision of Dr. Alain Moreau, Dr. Abdellatif Abouelseoud will work to develop a test to assess the risk of early OA progression by identifying biomarkers in the plasma of joint blood proteins and measuring changes in their levels. Development of such a test may lead to better management of symptoms and less disability for people with OA.  

Project title: Cognitive dysfunction and cognitive fatigue in SLE: A pilot study examining the underlying mechanisms with structural and functional MRIs of the brain

Annual commitment (plus 50/50 match):
Year 1: $20,000

Project summary: Brain fog in systemic lupus erythematosus may be the result of an overworking brain

People with systemic lupus erythematosus (SLE) commonly struggle with “brain fog”, a feeling of mental fatigue that can lead to problems with cognitive functions like memory and attention. The brains of those with SLE must work harder during cognitive tasks, in part leading to fatigue and memory issues. These challenges significantly affect quality of life and to date there are few treatment options available. Under the supervision of Dr Zahi Touma, Dr. Michelle Barraclough will use functional Magnetic Resonance Imaging (fMRI), a brain imaging tool, to collect more information about how the brain works when people with SLE do tasks that test their memory and attention and how fatigued they get during these tasks. Information from this study will help to develop personalised clinical trials to improve cognitive problems in people with SLE. 

Project title: Role of platelets in the recruitment of neutrophils in inflamed joints in rheumatoid arthritis

Annual commitment (plus 50/50 match):
Year 1: $20,000
Year 2: $20,000
Year 3: $20,000

Project summary: Role of platelets in the recruitment of white blood cells in joints in rheumatoid arthritis

Platelets are blood cells that help the body form clots to stop bleeding. Dr. Eric Boilard’s research has previously shown that platelets are also involved in arthritis. The team found that white blood cells, called neutrophils, can increase pain by leaving blood vessels and invading the joints. Platelets may reduce pain by limiting neutrophil recruitment to the joints. Under the supervision of Dr. Boilard, Dr. Marie Bellio will analyze interactions between platelets and neutrophils and then block these interactions to quantify pain in mice. This study may identify how to change the interactions between neutrophils and platelets to reduce pain, leading to the development of a new therapy for pain management in rheumatoid arthritis.

Project title: Intra-articular therapies for knee osteoarthritis: network meta-analysis and bayesian design for a randomized controlled trial

Annual commitment (plus 50/50 match):
Year 1: $25,000
Year 2: $25,000

Project summary: Comparing intra-articular therapies for knee osteoarthritis

Effective pain relief and maintenance of physical function are the primary objectives of medical treatment for osteoarthritis (OA). However, existing treatments can fall short of meeting these objectives or have safety issues. To address this, and under the supervision of Dr. Peter Juni and Dr. Bruno da Costa, Pavlos Bobos will combine evidence from well-designed studies available in the scientific literature using network meta-analysis (NMA). This work will help to determine which intra-articular therapies in knee OA appear to have the greatest impact in a single analysis. The research team will then use data from the NMA to design a new trial to determine the true effectiveness and safety of intra-articular therapies for knee OA. Identifying the therapies that are most effective will help to personalize treatment for people with knee OA. 

Project title: Epigenomic predictors of psoriatic arthritis in patients with psoriasis

Annual commitment (plus 50/50 match):
Year 1: $20,000
Year 2: $20,000

Project summary: Predictors of psoriatic arthritis

Psoriatic arthritis (PsA) is a type of inflammatory arthritis that often appears in people with a skin disease called psoriasis. Early diagnosis and treatment are important to reduce joint damage, however, many individuals with PsA remain undiagnosed because currently there is not a test to predict which people with psoriasis will develop PsA and which will not. Under the supervision of Dr. Dafna Gladman, Dr. Omar Cruz Correa will study how epigenetics, mechanisms that switch genes on and off, influence PsA risk and progression. The differences in these mechanisms may be used to predict which patients will develop PsA. This would allow patients at higher risk to be monitored more closely, and therapy to be personalized, preventing further joint damage and disability.

Project title: The impact of antimalarial drugs in arthritis patients exposed to SARS-CoV-2 – the CoVIRAL project

Annual commitment:
Year 1: $100,000
Year 2: $100,000
Year 3: $100,000

Project summary: What is the impact of antimalarial drugs in people with arthritis exposed to COVID-19?

People with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) have a compromised immune system but it is not known if they are at increased risk of COVID-19. Dr. Paul Fortin is studying people with RA and SLE to determine if those who are taking the antimalarial drugs, chloroquine or hydroxychloroquine, for their arthritis symptoms, are affected differently by COVID-19 than those who are not taking the drugs. The study will also examine the psychosocial impact of a serious infection in people with arthritis. The current COVID-19 pandemic offers a unique opportunity to enhance the understanding of how people with autoimmune inflammatory diseases like RA and SLE respond to infection.

Project title: Cannabis-based precision medicine for osteoarthritis therapy

Annual commitment (co-funded by CIHR-INMHA):
Year 1: $299,799
Year 2: $299,115
Year 3: $299,940
Year 4: $295,637
Year 5: $299,900

Project summary: Personalized medicine for osteoarthritis using cannabis

Osteoarthritis (OA) is a leading cause of disability, in part due to a lack of effective treatment options. Medical cannabis may offer a promising alternative, but its therapeutic benefits and harms likely depend on the characteristics of both the strain used and the individual patient treated. Dr. Hance Clarke is studying the effects of different active cannabis ingredients on different types of OA and identify patient traits that predict how they will respond. This will build the evidence base behind the use of medical cannabis for OA and help healthcare providers and patients personalize their treatment plans.

Project title: Cryptic pericellular matrix peptides: Bioactive molecules for osteoarthritis treatment

Annual commitment (co-funded by CIHR-IMHA):
Year 1: $125,000
Year 2: $125,000
Year 3: $125,000

Project summary: Bioengineering a new approach to osteoarthritis treatment

Millions of Canadians face the pain of osteoarthritis (OA), the most common form of arthritis, which has no cure. Recent advances have led to new biomaterials that can stimulate short-term tissue repair in the joint, but inflammation interferes with their effectiveness. To develop new and improved biomaterials to repair joint cartilage, Dr. Jean-Philippe St-Pierre is studying how cartilage responds to everyday forces to learn how to keep it healthy and protected from inflammation. This will inform the design of new long-acting biomaterials to promote tissue regeneration and cartilage repair as a novel approach to OA treatment.

Project title: Interfering with the HLA-antigen interaction: Towards a safe therapeutic for rheumatoid arthritis and new immunological probes

Annual commitment (co-funded by CIHR-IMHA): 
Year 1: $125,000
Year 2: $125,000
Year 3: $125,000

Project summary: Developing a new highly specific treatment for rheumatoid arthritis

There is currently no cure for rheumatoid arthritis (RA), an autoimmune disease caused by the immune system attacking the body’s own proteins. Many current RA treatments work by “turning down” the immune system in general, but this can put people at risk of infections or other diseases. Dr. John Trant is designing an entirely new class of drug that specifically targets the molecular interaction in the immune system responsible for RA to potentially avoid these pitfalls. If successful, this will pave the way for a new RA treatment with fewer side effects and will provide researchers with new chemical tools to help them better understand how the disease works.

Project title: Risk of infections with tumour necrosis factor inhibitors (TNFi) in pregnant women and their offspring

 Annual commitment:
Year 1: $125,000
Year 2: $125,000
Year 3: $125,000

Project summary: Understanding the safety of biologics in pregnancy

Many people with inflammatory arthritis (IA) who become pregnant are concerned about how their medications could affect them and their baby. But for many drugs used to treat IA, such as biologics called tumour necrosis factor inhibitors (TNFi), there is no clear answer – particularly regarding infection risk. Dr. Évelyne Vinet will assess the risk of serious infections associated with TNFi drugs in pregnant people and their babies by creating the largest dataset of this type ever assembled. Her results will help guide best clinical practices for the care of people requiring TNFi therapy during pregnancy and improve the health of their babies, reducing the burden of infections in this population.

Project title: Preventing osteoarthritis after a sport-related knee injury

Annual commitment:
Year 1: $124,960
Year 2: $124,985
Year 3: $124,944

Project summary: Overcoming obstacles to prevent osteoarthritis after a sport-related injury

In Canada, approximately 200,000 youth suffer a sport-related knee injury every year that puts them at risk of developing osteoarthritis (OA) at a young age. Currently, little effort is made to prevent OA when an athlete hurts their knee. With a team of patients and healthcare practitioners, Dr. Jackie Whittaker developed a first-of-its-kind physiotherapist-guided OA risk reduction program for young athletes with knee injuries. Using feedback from former and currently injured athletes, Dr. Whittaker will refine the program and test whether it can reduce two important risk factors for knee OA – knee muscle weakness and inactivity. This will inform larger-scale studies to help prevent OA in active young people.

Project title: Using real world data to enhance patient care and outcomes and health system performance for rheumatic and musculoskeletal diseases

Annual commitment:
Year 1: $50,000
Year 2: $50,000
Year 3: $50,000

Project summary: Using real-world data to enhance arthritis care and improve patient outcomes

The growing burden of arthritis and other similar diseases is a major problem facing our strained healthcare system, as well as people living with the disease and their caregivers. To understand this burden, improve care provided by physicians, rheumatologists and orthopaedic surgeons, and improve patient management within the healthcare system, decision-makers need high-quality evidence to directly inform clinical and public health policies. Dr. Jessica Widdifield is using real-world health data (e.g., data on doctor visits, hospital data, and electronic medical records) in Ontario to fill this gap. This will help improve healthcare system performance, quality of care, and ultimately patient outcomes.

Project title: A Better Match: Transforming rheumatoid arthritis care through tailored follow-up strategies based on disease activity and patient complexity, a pragmatic randomized controlled trial

Annual commitment (funded by CIHR-IMHA):
Year 1: $124,995
Year 2: $124,840
Year 3: $124,990

Project summary: Matching care for rheumatoid arthritis to patients’ needs

There is a crisis in healthcare for Canadians living with rheumatoid arthritis (RA), who often face barriers in receiving timely and effective care. While early and targeted therapy can prevent joint damage and complications, for many people with RA, the wait times to see a rheumatologist are long and scheduling of follow-up appointments rarely considers their individual needs. Dr. Claire Barber is assessing what type of follow-up RA patients need based on how active their disease is and their individual medical and health needs – whether that’s higher intensity care, or telehealth care through a “virtual clinic”. This will reveal whether this new approach can improve the quality of RA care.

Project title: Move Well Live Well: Using the science of movement to tailor exercise and rehabilitation for osteoarthritis to promote better living

Annual commitment (funded by CIHR-IMHA):
Year 1: $150,000
Year 2: $150,000
Year 3: $150,000

Project summary: Move well, live well: Using the science of movement to promote better living with osteoarthritis

Osteoarthritis (OA) is the most common from of arthritis and it is on the rise. Inactivity, obesity, and abnormal movements in the joint make knee OA worse. Dr. Monica Maly is using movement science to help people with knee OA tackle these problems and move more with less pain. She will tailor exercise plans for knee OA and combine them with a nutrition program to manage a healthy weight. Dr. Maly will also design and test a strategy to help people stick to these programs in the long term, and work to implement these programs in the community. Ultimately, this research will help improve quality of life for people with OA.

Project title: Investigating the pathogenesis of common spine disorders: Discovery-based approaches to identify therapeutic targets

Annual commitment (funded by CIHR-IMHA):
Year 1: $150,000
Year 2: $150,000
Year 3: $150,000

Project summary: Targeting back pain by finding the cause of common spine disorders

Back pain is the most common cause of disability worldwide, causing tremendous suffering in Canadians. Though the specific causes of back pain are not understood, in arthritis it is often associated with degeneration of the intervertebral discs, the joints that anchor vertebrae along the spine. Although disc degeneration is extremely common, very little is known about what causes it. Dr. Cheryle Séguin is studying the biology of disc degeneration and common spine disorders and testing potential new treatments in mouse and human model systems. The hope is that this research will translate from lab bench to bedside, leading to new treatments to prevent back pain.

Project title: Role of discoidin domain receptor 1 in T cell migration and arthritis

Annual commitment:
Year 1: $120,000
Year 2: $120,000
Year 3: $120,000

 Project summary: Targeting the movement of inflammatory cells to treat rheumatoid arthritis

Rheumatoid arthritis (RA) is an inflammatory disease driven by the abnormal activation of immune cells and their infiltration into the joints. Specific types of inflammatory immune cells orchestrate joint damage once they move into the joints, but exactly how they migrate there isn’t clear. Using mouse models that mimic human RA, Dr. Fawzi Aoudjit is determining if blocking a protein thought to be involved in guiding the immune cells into the joint can treat RA in the mice. If successful, this work could lead to a potential novel therapeutic strategy for the treatment of RA.

Project title: Platelets and neutrophils: The two culprits mediating pain in inflammatory arthritis

Annual commitment:
Year 1: $120,000
Year 2: $120,000
Year 3: $120,000

Project summary: Understanding how cells in the blood promote arthritis pain

Joint inflammation can cause devastating pain in arthritis, but how this occurs is not well understood. Defining which cells and molecules mediate arthritis pain is a crucial piece of the puzzle. Dr. Éric Boilard is studying mouse models that mimic human arthritis and examining the blood of people with arthritis to understand how different blood cells mediate pain in arthritis. Specifically, this study will be the first to examine how blood platelets (often known for their role in blood clotting) help neutrophils (immune cells) to mediate pain and whether this can be blocked. This could eventually lead to new treatment strategies for arthritis pain.

 

Project title: Identifying the origin of new bone formation in spondyloarthritis and targeting Macrophage Migration Inhibitory Factor (MIF) to stop osteoproliferation in a pre-clinical study

Annual commitment:
Year 1: $120,000
Year 2: $120,000
Year 3: $119,856

Project summary: Tackling inflammation and bone fusion in ankylosing spondylitis

Ankylosing Spondylitis (AS) is a severe, disabling form of spine arthritis characterized by inflammation and bone fusion in the spine and joints. Current treatments control inflammation in only half of patients and don’t address spinal fusion. Dr. Nigil Haroon is studying a molecule named MIF that plays a pivotal role in the inflammation and bone fusion seen in AS. This study will confirm whether blocking MIF in mice with AS can slow their disease. If successful, this research could lead to clinical trials of novel drugs that can block MIF to confirm their safety and effectiveness in humans. This type of treatment would be the first to tackle both inflammation and bone fusion at the same time.

Project title: New dietary and exercise intervention strategies for patients with obesity and osteoarthritis of the knee: Translating preclinical innovation to patient populations

Annual commitment:
Year 1: $120,000
Year 2: $120,000
Year 3: $120,000

Project summary: Preventing osteoarthritis by tackling obesity with diet and exercise

Osteoarthritis (OA) and obesity are both increasing at exponential rates. OA and obesity have been linked, but little is known about how to effectively prevent obesity-induced OA. Dr. Walter Herzog is addressing this problem by studying obesity, metabolic changes, and changes in the microbes in the gut of rodents fed a high-fat and high-sugar diet, which triggers the development of knee OA. He will see if a prebiotic fibre diet and/or an exercise program can prevent OA from developing, and how early intervention is needed. This will inform a clinical trial in people living with obesity and knee OA. If successful, this could reveal a strategy for preventing OA through lifestyle management.

Project title: T cell dysregulation in ankylosing spondylitis

Annual commitment:
Year 1: $120,000
Year 2: $120,000
Year 3: $120,000 

Project summary: How the immune system goes awry in ankylosing spondylitis

Ankylosing spondylitis (AS), the most common form of inflammatory spine arthritis, can have a devastating impact on quality of life due to pain and disability. Current treatments improve symptoms in some people, but they don’t reliably stop progressive damage to the spine and they are not cures. Inflammation in AS is likely driven by specialized immune cells that are normally controlled by checkpoints in the immune system. Dr. Robert Inman is studying how these immune checkpoints and cells go wrong in people with AS to understand the molecular basis of the chronic inflammation that causes the disease. These insights could open the door to new approaches to personalized treatments.

Project title: Obesity, disc degeneration and back pain: Nuclear receptors as therapeutic targets

Annual commitment:
Year 1: $120,000
Year 2: $120,000
Year 3: $120,000

Project summary: Obesity and back pain: On the road to new therapies

Back pain is the most common cause of disability worldwide. Though the causes of back pain are complex, it is often associated with degeneration of parts of the spine called intervertebral discs. There are no treatments to stop disc degeneration since we do not understand the molecular pathways driving the disease. Dr. Cheryle Séguin is using animal models and human tissues to study the links between obesity, changes in specific proteins, disc degeneration and back pain. This study will help reveal whether therapeutically targeting a specific molecular pathway can alter disease progression and symptoms, potentially revealing a new treatment strategy.

Arthritis Centres are the rheumatology divisions of the departments of medicine in Canadian universities, including accredited pediatric rheumatology centres.

For over 50 years, the Arthritis Society has provided funding to support Arthritis Centres across Canada. As centres of clinical expertise, research, and education, their role in the Canadian healthcare environment is to help ensure that Canadians with arthritis receive the best care.

Through these funding commitments to Arthritis Centres, the Arthritis Society supplements and leverages resources at medical schools and raises the profile of arthritis within universities. This supports the Arthritis Centres’ capacity to provide exemplary patient care, ensure high standards of graduate and undergraduate teaching, and develop excellent opportunities for clinical and basic research.

The 2019-20 Arthritis Centre Grants support centres that align with one of the Arthritis Society’s primary strategic areas of focus – building and supporting a pipeline of strong researchers. These grants support capacity building programs at Arthritis Centres with an aim to increase the number of academic rheumatologists in Canada and/or to support research training in rheumatology.

The 2019-20 recipients of up to $15,000 for a term of one year are:

• Centre hospitalier universitaire de Sherbrooke (CHUS)
• CHU de Québec – Université Laval
• McMaster Children’s Hospital
• McMaster University
• Montreal General Hospital, McGill University Health Centre
• The Hospital for Sick Children
• The Ottawa Hospital
• University of Alberta
• University of Manitoba Arthritis Centre
• University of Saskatchewan

Project title: Identification and characterization of mesenchymal stem cells with increased cartilage regeneration potential

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Finding the best stem cells for osteoarthritis therapy

Millions of Canadians are faced with the pain of osteoarthritis (OA) – a debilitating disease with no cure. Some researchers are investigating whether stem cell therapy, using a person’s own cells to heal their joints, has the potential to be a game-changing approach to OA treatment. Under the supervision of Dr. Roman Krawetz, Nedaa Aljezani is learning how to distinguish the best stem cells with the most potential to help patients repair their joint cartilage, which will help design better clinical trials to test the promise of stem cell therapy for OA.

Project title: Derivation and validation of a disease-specific cardiovascular risk prediction score for psoriatic disease using patient registry data

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Scoring personal risk for heart attack and stroke in people with psoriatic disease

Psoriatic disease (PsD) is a chronic inflammatory skin and joint disease that includes psoriasis and psoriatic arthritis. People with PsD are more likely to develop cardiovascular diseases, such as heart attack and stroke, but doctors need a better way to predict which patients have the highest risk. Under the supervision of Dr. Dafna Gladman and Dr. Lihi Eder, Keith Colaço is studying data from thousands of people with PsD to develop a simple risk score to help doctors recommend treatments to lower patients’ personal risk of cardiovascular diseases. For people with PsD, this could lead to healthier, longer, and better-quality lives.

Project title: The role of platelet signalling in inflammatory arthritis

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Discovering how blood platelets contribute to rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic and painful inflammatory disease that reduces life expectancy and quality of life. Researchers are beginning to learn about how blood platelets (often known for their role in blood clotting) contribute to inflammation and RA development. Under the supervision of Dr. Hugh Kim, Enoli De Silva is studying whether blocking a molecular signal from platelets can dampen inflammation and whether blood levels of these molecules are linked to RA severity. This new understanding of how RA works could help lead to new treatments or improve diagnosis.

Project title: Understanding the biological and clinical features of diffuse idiopathic skeletal hyperostosis (DISH)

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Understanding DISH: An underdiagnosed form of painful spine arthritis

Diffuse idiopathic skeletal hyperostosis (DISH) is a relatively common form of arthritis that involves hardening of ligaments and connective tissues resulting in “bony bridges” between segments of the spine. Very little is known about what causes DISH, especially in its early stages. The disease can cause pain and, in advanced cases, even problems swallowing or breathing. Under the supervision of Dr. Cheryle Séguin and Dr. Michele Crites Battié, Dale Fournier is undertaking a detailed study of how, when and where bony bridges form in DISH and their impact on pain. This fundamental knowledge will influence how doctors diagnose and care for people with this disease.

Project title: Health-related quality of life following a youth sport-related knee injury: Implications for preventing post-traumatic osteoarthritis and promoting lifelong well-being 

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500

Project summary: The importance of overall well-being in youth following a sport-related knee injury

In Canada, as many as 1 in 3 youth get injured playing sports every year. In the case of knee injuries, this puts them at risk of early-onset osteoarthritis (OA). Often, a good recovery is defined as being able to return to playing sports. But this definition misses the longer-term impacts of injury on the physical, mental and social aspects of overall well-being. Under the supervision of Dr. Jackie Whittaker, Christina Le is studying the well-being of active youth who have recently had a knee injury compared to their uninjured peers over the course of a year. The study’s findings will inform rehabilitation strategies to empower injured youth to pursue lifelong wellness and prevent OA.

Project title: Economic evaluation of group-based exercise therapy in comparison to usual care for hip and knee osteoarthritis in Alberta

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Informing public funding decisions for an exercise and education program for osteoarthritis

Moving stiff and painful limbs is the last thing someone wants to do when their joints ache from osteoarthritis (OA), but exercise can have many benefits. Researchers have previously developed an exercise and education program that lowered pain intensity and medication usage in people with OA. A pilot study of this 8-week program is being run at rehabilitation clinics across Alberta. Under the supervision of Dr. Deborah Marshall, Darren Mazzei is comparing the health benefits and economic costs of the pilot program with those of the usual approach to OA care. These results will directly inform provincial decision-makers examining whether to publicly fund the program in Alberta.

Project title: Genetic predictors for non-responders to total joint replacement therapy in primary osteoarthritis patients

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Identifying genetic factors behind failed joint replacements

While some treatments can help manage the pain of osteoarthritis (OA), advanced cases may need to be managed with total joint replacement surgery. After surgery, most people find that their pain is reduced and their joint works better. But for others, their symptoms may stay the same or even get worse. Under the supervision of Dr. Guangju Zhai, Salem Werdyani is studying the DNA of people who responded well or poorly to joint replacement surgery to discover what genetic factors might predict a poor outcome. This could help doctors and their patients decide whether joint replacement is the right choice and, if so, help patients better prepare for their surgery and recovery.

Project title: The resistance of T lymphocytes to anti-arthritic treatments: Role of integrin alpha 2 beta 1

Annual commitment (plus 50/50 match):
Year 1: $20,000

Project summary: Understanding resistance to a common medication for inflammatory arthritis

Methotrexate is one of the most common medications used to treat forms of inflammatory arthritis (IA), such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). However, not all people respond well to it, or they may develop resistance to it over time. Why this happens is not yet clear. Under the supervision of Dr. Aoudjit Fawzi, Dr. Amna Abderrazak is studying how certain immune cells are able to evade the drug’s effects, including the impact of a molecule thought to be protecting the cells. This study could reveal a new treatment strategy to improve the effectiveness of methotrexate.

Project title: TRAF1 is the key modulator of the inflammatory pathway leading to arthritis: A potential good target for therapy

Annual commitment (plus 50/50 match):
Year 1: $20,000
Year 2: $20,000
Year 3: $20,000

Project summary: Understanding a key molecular player in inflammatory arthritis

Excessive inflammation is the root cause of many debilitating human diseases, including inflammatory arthritis (IA). Understanding how the body keeps inflammation in check is essential to discovering new treatment approaches for IA. People with a variant of a gene called TRAF1, recently implicated in inflammation, have a higher risk of rheumatoid arthritis (RA) or juvenile idiopathic arthritis (JIA). Under the supervision of Dr. Ali Abdul-Sater, Dr. Ali Akram is studying how TRAF1 works as a “brake” on inflammation in these two forms of IA. These insights will help TRAF1 be developed as a novel therapeutic target for IA.

Project title: Senolytics to reduce intervertebral disc degeneration and back pain

Annual commitment (plus 50/50 match):
Year 1: $20,000
Year 2: $20,000
Year 3: $20,000

Project summary: Removing “zombie” cells to reduce pain and degeneration in the spine

Degeneration of parts of the spine can cause debilitating back pain and osteoarthritis (OA). While some treatments can help manage the pain, there is no cure or way to prevent the degeneration from progressing. Researchers have found that “zombie” cells – ones that have stopped multiplying themselves but haven’t died – may play a key role in spine degeneration. Under the supervision of Dr. Lisbet Haglund, Dr. Hosni Cherif is studying whether an approved drug or a natural chemical found in plants can be repurposed to wipe out these cells to improve spine health. This could lead to an entirely new treatment approach for spine OA and back pain.

Project title: Promoting rational glucocorticoid tapering: A pilot project at a vasculitis referral centre

Annual commitment (plus 50/50 match):
Year 1: $25,000

Project summary: Improving patient safety by managing the use of steroid treatments

Steroids are widely used to treat many forms of arthritis and associated conditions like vasculitis, an autoimmune disease involving inflammation of the blood vessels that can cause arthritis, organ damage, and even death. But steroids can cause dangerous side effects if they’re used for too long. Under the supervision of Dr. Christian Pagnoux, Dr. Arielle Mendel is studying whether doctors are currently following best practices in tapering off steroid treatment over time in vasculitis patients and, if not, what underlying issues (e.g. wait times, doctor education) need to be tackled. This will help improve patient safety and quality of care.

Project title: Pro-inflammatory platelet signaling in juvenile arthritis

Annual commitment (plus 50/50 match):
Year 1: $20,000
Year 2: $20,000
Year 3: $20,000

Project summary: Discovering how blood platelets contribute to childhood arthritis

Childhood arthritis is a devastating disease that can cause severe pain and disrupt growth. But predicting which children are at risk of more severe forms of the disease is an ongoing challenge. Researchers are beginning to learn about how blood platelets (often known for their role in blood clotting) contribute to inflammation and childhood arthritis. Under the supervision of Dr. Hugh Kim, Dr. Manoj Paul is studying how a molecular signal released from platelets contributes to tissue damage in childhood arthritis and whether blood levels of these molecules are linked to disease severity. These new insights could help improve the diagnosis and treatment of children living with arthritis.

Project title: Understanding the mechanism of anti-inflammatory action of mesenchymal stromal cells in osteoarthritis

Annual commitment (plus 50/50 match):
Year 1: $20,000
Year 2: $20,000
Year 3: $20,000

Project summary: Developing a “super cell” therapy for osteoarthritis

Millions of Canadians are faced with the debilitating pain of osteoarthritis (OA). With support from the Arthritis Society, Dr. Sowmya Viswanathan’s team led the first Canadian clinical trial of an innovative therapy for OA where pro-healing cells from a patient’s own bone marrow were injected into their joint to reduce inflammation and OA symptoms. Since this worked better in some patients than others, Dr. Razieh Rabani is investigating what makes the cells work, under the supervision of Dr. Viswanathan. This will help predict and improve the cells’ potency, which could translate into a “super cell” therapy to be tested in future clinical trials to potentially transform the OA treatment landscape.

Project title: CD8 T cell dysregulation in ankylosing spondylitis

Annual commitment (plus 50/50 match):
Year 1: $20,000
Year 2: $20,000
Year 3: $20,000

Project summary: Profiling immune cells to tackle ankylosing spondylitis

Ankylosing spondylitis (AS) is a chronic, painful, and debilitating form of inflammatory arthritis (IA) that can be challenging to diagnose. Left unchecked, the inflammation of AS can lead to total fusion of the spine and marked disability. Under the supervision of Dr. Robert Inman, Dr. Michael Tang is investigating the emerging role of specific immune cells in AS by studying their molecular profile in the blood and joint fluid of people living with the disease. This detailed study will be the first of its kind, and its findings could shed light on new opportunities to diagnose AS early and develop new treatments. 

 

Arthritis Centres are the rheumatology divisions of the departments of medicine in Canadian universities, including accredited pediatric rheumatology centres.

For over 30 years, the Arthritis Society has provided annual funding to Arthritis Centres across Canada. As centres of clinical expertise, research, and education, their role in the Canadian healthcare environment is to help ensure that more Canadians with arthritis receive better care.

Recipients of up to $15,000 for a term of one year (2018/19) are:

• BC Children’s Hospital, University of British Columbia
• CHU de Quebec, Université Laval
• QEII Health Science Centre, Dalhousie University
• McMaster University
• McMaster Children’s Hospital, McMaster University
• St. Joseph’s Health Centre, Western Ontario
• SickKids Hospital, University of Toronto
• Montreal Children’s Hospital, McGill University
• University of Manitoba
• University of Calgary
• University of Alberta

Arthritis Centre grants support centres that align with one of the Arthritis Society’s primary areas of focus – to build and support of pipeline of strong researchers. Proposal objectives support capacity building programs with an aim to increase the number of academic rheumatologists in Canada and/or to support research training in rheumatology.

Project title: A mouse model to design therapies targeting TRAF1 in rheumatoid arthritis

Annual commitment:
Year 1: $125,000
Year 2: $125,000
Year 3: $125,000

Project summary: Learning how to put the brakes on rheumatoid arthritis

Rheumatoid arthritis (RA) is an inflammatory disease where the body’s immune system starts to attack the lining of the joints. Understanding more about how the body usually keeps inflammation in check, and how this goes wrong in RA, can help researchers design new treatments. Dr. Ali Abdul Sater is launching his arthritis research career by studying a protein that acts as a “brake” on inflammation, which may be a good target for future RA therapies. By developing a new, unique mouse model to study in the lab, Dr. Abdul Sater will discover how this protein can be manipulated to effectively treat RA. New RA treatments could improve health outcomes and give patients more options.

Project title: Genetics of manifestations and complications of systemic lupus erythematosus

Annual commitment:
Year 1: $125,000
Year 2: $125,000
Year 3: $125,000

Project summary: Leading the way in genetic studies of systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a life-threatening inflammatory disease for which there is no cure. About 1 in 5 of those diagnosed with SLE are children or adolescents, who have a higher risk of suffering from disease complications and treatment side effects. Genetic differences have important effects on who gets SLE, how it manifests, and what complications arise. Dr. Linda Hiraki is launching her research career by leading a coordinated effort to study how genetic changes (especially rare ones) affect SLE and its complications in children and adults across North America. This knowledge will lead to improved care and enable the discovery of new treatments.

Project title: Advanced multimodal imaging to predict early inflammatory arthritis progression

Annual commitment:
Year 1: $124,960
Year 2: $124,660
Year 3: $124,910

Project summary: A triple threat for imaging joint damage in rheumatoid arthritis

People with rheumatoid arthritis (RA) experience swelling and bone damage in their joints, but how damage starts and gets worse is unclear. Launching her career in arthritis research, Dr. Sarah Manske is using specialized medical imaging to understand how joint swelling and bone changes are connected. Magnetic resonance imaging (MRI) and ultrasound are very good for looking at the swelling in the soft tissues of the joints. Computed tomography (CT) is very good for looking at the bones. By combining all three types of imaging, Dr. Manske will follow how joint damage happens in the hands of people with RA. This research will help guide more effective treatment strategies to minimize joint damage.

Project title: Establishing the validity of quality of life measures in young children with juvenile idiopathic arthritis

Annual commitment:
Year 1: $102,794
Year 2: $119,705
Year 3: $101,540

Project summary: Quality of life in childhood arthritis: How do we measure up?

Understanding the impact of childhood arthritis on quality of life, and how this changes with treatment, is a crucial factor for considering how to make the most of limited healthcare resources and improving childhood arthritis care in Canada. Current methods for measuring quality of life have not been tested in children with arthritis, or in children under eight years old. Dr. Susanne Benseler is collecting quality of life data from the families of young children with arthritis using a survey tool to test if this approach captures the pain of childhood arthritis and its impacts on life in a meaningful way. This will improve how quality of life is measured in children with arthritis, providing an approach that could become the standard in research and clinical practice.

Project title: Randomized controlled trial of staged versus simultaneous bilateral knee arthroplasty

Annual commitment:
Year 1: $119,940
Year 2: $118,120
Year 3: $120,000

Project summary: Replacing both knees due to severe osteoarthritis: One at a time, or both together?

For some people with osteoarthritis (OA), joint replacements are the only option to relieve the pain and restore function. When both knees need to be replaced, it’s not yet clear whether it’s better for the patient to replace them both at the same time in one operation, or stage the two replacements a few months apart. Both approaches have pros and cons with respect to how the patient recovers from surgery. Dr. Eric Bohm is leading a clinical trial across Canada to compare the two approaches in terms of recovery times, pain relief, joint function, patient satisfaction, and time off work. The results will be used to help patients make informed choices about what surgical approach is best for them.

Project title: Mapping the epidemiology and the role of treatments in mental health complications in inflammatory arthritis (MATTERS)

Annual commitment:
Year 1: $65,073
Year 2: $57,125
Year 3: $84,748

Project summary: Mental health matters in arthritis

The physical effects of arthritis are undeniable and devastating. However, arthritis also has a complex relationship with mental health. Having arthritis may lead to depression or anxiety, and in turn, depression and anxiety can worsen arthritis. Dr. Mary De Vera is using “big data” (e.g., many records of doctors’ visits, hospitalizations, and prescriptions) to study whether the burden of depression and anxiety in British Columbians with arthritis is increasing over time and the effect of other contributing factors, such as medication use. This will be the first study of its kind in Canada on mental health in arthritis. It will not only help improve the lives of people with arthritis but will also bring more awareness to this important matter.

Project title: The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis (OPT-JIA)

Annual commitment:
Year 1: $120,000
Year 2: $102,400
Year 3: $97,936

Project summary: A clinical trial to prevent side effects of treatment in children with arthritis

Many children with arthritis are treated with methotrexate, a drug commonly used in chemotherapy that also effectively controls joint swelling. While this drug has major benefits, too many children with arthritis have nausea and vomiting as a side effect. This can impact every facet of life for children and their families, so many children switch to treatment with expensive biologics, even if methotrexate was working. Dr. Jaime Guzman is leading a clinical trial to see if a drug called ondansetron can prevent nausea and vomiting in children with arthritis starting methotrexate, allowing them to continue methotrexate treatment if it is effective. If successful, this trial could influence clinical practice to improve quality of life for children with arthritis and their families.

Project title: Proof-of-concept study of an electronic medical record (EMR) reminder intervention to optimize the primary and secondary prevention of comorbidities in people with inflammatory arthritis

Annual commitment:
Year 1: $120,000
Year 2: $120,000
Year 3: $120,000

Project summary: Empowering doctors to prevent chronic health problems in people with inflammatory arthritis

The inflammation that causes joint pain in inflammatory arthritis (IA) may also put people at risk for other chronic health problems such as heart disease, diabetes, osteoporosis, infections, and some cancers. These serious co-existing health conditions can compromise quality of life and even lead to early death. Dr. Diane Lacaille is developing and testing an automated way to send family doctors timely reminders to check for and manage risk factors for chronic diseases in their patients who have IA. This will help them establish effective prevention strategies to keep people with IA as healthy as possible so they can live long, full lives.

Project title: Identification of mitochondrial antigens targeted by auto-antibodies in systemic lupus erythematosus (SLE)

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Examining the immune reactions in systemic lupus erythematosus

Mitochondria are small structures inside cells that are believed to have evolved from bacteria. If cells are damaged and mitochondria are released outside, the body’s immune system can mistake them for bacteria and mount an immune response as if there was an infection. This immune overreaction takes place in systemic lupus erythematosus (SLE), an autoimmune form of arthritis. Under the supervision of Dr. Éric Boilard, Yann Becker will study how mitochondria are recognized by the immune system in SLE and to identify signs that may help improve SLE diagnosis or predict how it will progress. This could lead to new clinical tests to help ensure that people with SLE receive the best care possible.

Project title: Investigating the therapeutic role of ex vivo polarized monocytes/macrophages in osteoarthritis

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500

Project summary: Using a person’s own immune cells as a therapy for osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis, affecting millions of Canadians. While there are several strategies to manage the pain and other symptoms of OA, there is no cure and advanced disease can require surgical joint replacement. Under the supervision of Dr. Sowmya Viswanathan, Mable Wing Yan Chan is investigating an innovative new approach to OA therapy – using the body’s own immune cells. This study will test whether immune cells can be taken out of the blood and “trained” in the lab to reduce inflammation and joint damage, before being injected back into human joint tissues. This research could lead to a completely new, personalized approach to OA treatment.

Project title: Cost-effectiveness of early and aggressive treatment for children with juvenile idiopathic arthritis including the spillover effects on quality of life and productivity of children and their parents

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Understanding the costs of childhood arthritis – for the whole family

Arthritis can affect people at any age, including children. While the development of new therapies for childhood arthritis has made a tremendous difference to affected children and their families, new medications are expensive, and all have risks as well as benefits. Under the supervision of Dr. Deborah Marshall, Luiza Grazziotin is studying the impact that early treatment of childhood arthritis has on parents’ quality of life and their family’s financial well-being. This broader understanding of the burden of childhood arthritis on families may help inform drug reimbursement decisions to support optimal care for children with arthritis across the country.

Project title: Bone marrow lesions and cartilage mechanical properties in osteoarthritis

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Understanding how bone bruises contribute osteoarthritis

“Bone bruises” are areas of damage commonly seen on medical imaging scans of people with osteoarthritis (OA) in the knee or hip. They have been linked to having higher levels of pain, and arthritis that worsens more quickly. However, it is unclear how bone bruises affect the bone are cartilage that lie over them, and the role they play in causing OA. Under the supervision of Dr. David Wilson, Carly Jones is measuring how bone bruises in the knee and hip joints affect the stiffness of nearby bone and cartilage to understand how they contribute to the pain and joint damage of OA. This information is essential to developing more effective ways to treat, slow, or stop the disease.

Project title: Beyond training: understanding patient/public experience of power dynamics as engaged partners in arthritis research

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Power dynamics experienced by patient partners in arthritis research

Engaging patients and other members of the public in health research in meaningful ways can ensure that research is informed by patient priorities and designed to have the most potential for impact. The arthritis research community has been a leader on this front, but there are still unanswered questions around how to best integrate these partners within research teams. Under the supervision of Dr. Linda Li and Dr. Laura Nimmon, Graham Macdonald is studying the power dynamics of arthritis research teams from the perspectives of both patient partners and researchers. These insights will help improve patient engagement in research, fostering research that involves and empowers people with arthritis to transform this disease.

Project title: Culture preconditioning strategies to enhance the therapeutic efficacy of adipose tissue-derived mesenchymal stromal cells for the treatment of osteoarthritis

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Harvesting cells from fat to treat osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis, which has a devastating impact on millions of Canadians. New treatment options are needed, because there is no cure and advanced cases may require surgical joint replacement. Under the supervision of Dr. Sowmya Viswanathan and Dr. Rajiv Gandhi, Kevin Robb is studying a new potential therapy that uses cells taken out of fat tissues that interact with the immune system, and injects them into affected joints. He will study how these cells work in detail, how they interact with joint tissues in OA, and whether they can be “trained” in the lab to reduce inflammation, joint damage and pain. This could lead to a new treatment to be tested in clinical trials.

Project title: CD154 and its receptors in rheumatoid arthritis

Annual commitment:
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: Towards a new targeted treatment strategy for rheumatoid arthritis

Rheumatoid arthritis (RA) involves inflammation triggered by many signals in the body, including signals from several proteins in the cell. Many of these signals are the targets of the class of RA drugs known as biologics – complex medications made by living cells. These drugs are expensive and, like all drugs, have side effects as well as benefits. Under the supervision of Dr. Walid Mourad, Suzanne Salti is studying an inflammatory signalling protein involved in RA and how it interacts with several novel protein partners. The goal is to exploit these discoveries to develop a new type of biologic – one that could potentially be less expensive and have fewer side effects.

Project title: Endothelial ephrin B4 and ephrin B2 signalling in tissue fibrosis

Annual commitment (plus 50/50 match):
Year 1: $10,500
Year 2: $10,500
Year 3: $10,500

Project summary: The biology behind a life-threatening complication in scleroderma

Scleroderma is a form of arthritis that involves a build-up of tough scar-like tissue in the skin and sometimes other organs through a process called fibrosis. In the joints, this can lead to stiffness and pain. If it affects the lungs, fibrosis can be life-threatening. Under the supervision of Dr. Mohit Kapoor, Brian Rai-Ling Wu is studying a specific protein involved in lung fibrosis to learn where it comes from and how it works, especially in the context of the cells that line the blood vessels. Pinpointing how this protein leads to lung fibrosis could lead to new treatments for this serious complication of scleroderma.

Project title: More than skin deep: the microbiome of psoriasis and psoriatic arthritis

Annual commitment (plus 50/50 match):
Year 1: $10,500

Project summary: The role of skin bacteria in psoriasis and psoriatic arthritis

Psoriasis is an inflammatory skin disease that can be associated with arthritis in up to 30% of the people who have it. Psoriatic arthritis (PsA) can lead to progressive joint damage, pain, disability, and poor quality of life, but its impact can be quite variable. This variation cannot yet be explained by known risk factors. Under the supervision of Dr. Vinod Chandran, Meital Yerushalmi is working on a first-of-its-kind study of skin bacteria in people with psoriasis and different types of PsA in the context of the person’s genetics. This research will reveal what role skin bacteria play in the development and severity of PsA, which could provide insight into possible new treatments.

Project title: microRNA discovery in early and late knee osteoarthritis using next generation sequencing

Annual commitment (plus 50/50 match):
Year 1: $20,000
Year 2: $20,000

Project summary: Towards a blood test for early detection of knee osteoarthritis

There is a significant gap in the care of people with osteoarthritis (OA) due to challenges in diagnosing it early and a lack of treatment options. Researchers are searching for signs in the blood that could help catch OA earlier. Dr. Shabana Ali is working towards discovering new ways to distinguish groups of people with knee OA based on their personal characteristics (e.g. age, sex, body mass index) and disease severity, using a cutting-edge technology to create “fingerprints” of molecules found in the blood. These results could be used to develop a simple blood test to diagnose early knee OA, which could allow people to begin exercise or physical therapy programs to prevent progression of the disease.

Project title: Role of microRNAs in preclinical rheumatoid arthritis

Annual commitment (plus 50/50 match):
Year 1: $20,000
Year 2: $20,000
Year 3: $20,000

Project summary: Learning more about how rheumatoid arthritis starts in a high-risk population

Rheumatoid arthritis (RA) is an inflammatory condition where body’s immune system attacks its own joints leading to pain and impaired mobility. Molecules that act as “switches” to turn genes on and off misbehave in some people with a high risk of RA, leading to inflammation and eventually the disease. Dr. Vidyanand Anaparti will study these molecules in children from Indigenous communities in Northern Manitoba who have a high risk of developing RA. In doing so, he will learn more about how these molecules work and whether they can help predict who will get RA. This could eventually lead to a blood test to catch RA early in this high-risk population, even before symptoms appear.

Project title: Improving strength training in people with rheumatoid arthritis: a foundational behaviour change science approach

Annual commitment (plus 50/50 match):
Year 1: $20,000
Year 2: $20,000
Year 3: $20,000

Project summary: Strength training for people with rheumatoid arthritis: promising strategies to get active

Current guidelines recommend that people with rheumatoid arthritis (RA) perform strength training exercises at least twice a week to build or maintain muscle, and reduce pain and fatigue. However, remarkably few people with RA meet this goal. This disparity highlights an important missed self-management opportunity. Dr. Jasmin Ma is studying what factors help and hinder participating in strength training among people with RA and will identify the best strategies to support their long-term engagement in this type of physical activity. These results will inform future health promotion efforts to empower people living with RA to improve their quality of life.

The CRA (CIORA)-AS Clinician Investigator Award is intended to provide new clinician investigators, within 5 years of a full time clinical faculty appointment, with what would usually be their first opportunity, upon completion of post graduate training, to demonstrate their ability to initiate and carry out independent research of clear relevance to arthritis, before becoming involved in carrying out the full clinical, teaching and research duties expected of a regular member of the university staff.

Awardees are expected to complete a research project during the term of this salary award. The proposed project must be of clear relevance to rheumatic diseases and be aligned with one or more of the research pillars under the Canadian Initiative for Outcomes in Rheumatology Care (CIORA) grant program.

• Awareness/Advocacy/Education
  1. Health Economics/Sustainability of Health Care/Quality Improvement
• Early Access for rheumatic diseases Patients
• Multi-Disciplinary Care Teams

Please visit the CRA website for the 2018 results.

Assistant Professor, Dept. of Medicine, Schulich School of Medicine & Dentistry, Western University 

Project Title: The dual role of synovial macrophages in post-traumatic and metabolic osteoarthritis.

Annual Commitment:
Year 1: $120,000
Year 2: $120,000
​Year 3: $120,000

Keywords: osteoarthritis, synovitis, articular cartilage, macrophage, inflammation, animal models of OA, early arthritis, flow cytometry, metabolic OA, post-traumatic OA

Project Summary:

• Why?: OA is different from other types of arthritis with high-grade inflammation (e.g. rheumatoid arthritis). OA presents with low-grade, chronic, and often intermittent inflammation. Research has shown that inflammation in the lining of joints from people and animals with OA contains high numbers of immune cells called macrophages.
• What?: This project proposes to answer these questions: 
  1. Are OA macrophages mainly pro-inflammatory or anti-inflammatory, and are they different in early vs. late stages, and in post-traumatic OA vs. metabolic OA?
  2. What are the gene expression profiles of OA macrophages in different stages and types of OA?
  3. Does treatment that specifically causes loss of macrophages reduce or accelerate OA, and does the effect depend on treatment timing or type of OA?
• How?: Use two animal models of post-traumatic OA to examine the knee joint tissues to assess whether the macrophages present in early and late knee OA are mostly pro-inflammatory vs. anti-inflammatory, and whether the macrophages occurring in each type of OA are different.
  
  Use advanced genetic tools to measure the expression of all macrophage genes, which will give us critical insight into how these cells are functioning at different stages of each type of OA.
  
  Use a treatment to selectively remove all macrophages from the rats while OA develops, or after OA has been established.
• Impact?: To help us understand if macrophages worsen or protect against knee OA, and whether these cells behave differently in early and late OA of different types.
  
  If a treatment is developed, the knowledge gained from these critical experiments may help us personalize how, when, and in which types of patients a macrophage targeting treatment might work best.
  
  To prepare us to test how we could strategically leverage the anti-inflammatory functions of macrophages in future studies to improve OA outcomes.

Project Lay Summary:

Osteoarthritis (OA) is by far the most common type of arthritis. Many people think OA is just “wear and tear” arthritis and don’t know that OA also involves inflammation. Importantly, OA is different from other types of arthritis with high-grade inflammation (e.g. rheumatoid arthritis). OA presents with low-grade, chronic, and often intermittent inflammation. Research has shown that inflammation in the lining of joints from people and animals with OA contains high numbers of immune cells called macrophages.

In this study, we will test whether macrophages play a critical role in the development and progression of two types of OA seen very commonly in people: OA after joint injury (post-traumatic OA), and OA with changes in the body’s metabolism such as obesity (metabolic OA). Interestingly, some macrophages promote inflammation while others help to control inflammation and promote tissue healing. However, a critical knowledge gap exists. It is unknown whether the main roles of macrophages are affected by different stages or different types of OA.

This project proposes to answer these questions: 1. Are OA macrophages mainly pro-inflammatory or anti-inflammatory, and are they different in early vs. late stages, and in post-traumatic OA vs. metabolic OA? 2. What are the gene expression profiles of OA macrophages in different stages and types of OA? 3. Does treatment that specifically causes loss of macrophages reduce or accelerate OA, and does the effect depend on treatment timing or type of OA?

Before we can safely answer these questions in humans, we need to acquire more information about the role of macrophages in OA by using two well-established animal models of post-traumatic OA and metabolic OA in rats. First, we will examine the knee joint tissues to assess whether the macrophages present in early and late knee OA are mostly pro-inflammatory vs. anti-inflammatory. We will also see whether the macrophages occurring in each type of OA are different.

Next, we will use advanced genetic tools to measure the expression of all macrophage genes, which will give us critical insight into how these cells are functioning at different stages of each type of OA. Finally, we will use a treatment to selectively remove all macrophages from the rats while OA develops, or after OA has been established. Comparing the severity of OA with and without macrophages, at different stages of the disease, and in different types of OA, will give us critical knowledge about these inflammatory cells. Our long-term goal is to find treatments for the symptoms and damage caused by OA in our patients.

This project will help us understand if macrophages worsen or protect against knee OA, and whether these cells behave differently in early and late OA of different types. If a treatment is developed, the knowledge gained from these critical experiments may help us personalize how, when, and in which types of patients a macrophage targeting treatment might work best. The study will also prepare us well to test how we could strategically leverage the anti-inflammatory functions of macrophages in future studies to improve OA outcomes.

Associate Professor, Dept. of Dentistry, Schulich Medicine & Dentistry, Western University

Project Title: YAP1: a novel target for scleroderma fibrosis?

Annual Commitment:
Year 1: $117,252
Year 2: $117,252
​Year 3: $117,252

Keywords: Scleoderma, conditional, fibrosis, adhesive signaling, connective tissue, skin, cell culture, fibroblast, TGF beta, microenvironment

Project summary:

• Why?: The most characteristic feature of scleroderma is the build-up of tough scar-like fibrous tissue in the skin. A cell type called the myofibroblast (a special form of fibroblast) is responsible for the overproduction of collagen and the development of tough scar tissue (a process called called fibrosis).  The toughness of the scar tissue itself in turn acts on myofibroblasts to generate more collagen and scar tissue.  We want to break this vicious cycle to treat scleroderma.
• What?: The aim of our project is to identify if a protein called YAP1 (found inside the fibroblast) is responsible for generating the toughness of scar tissue.
• How?: To test if:
  1. Visudyne can block the generation and activity of myofibroblasts, and
  2. The presence of YAP1 in fibroblasts is essential for the development of skin fibrosis in our animal models of scleroderma.
• Impact?: Our project could ultimately result in the use of these drugs to treat scleroderma.

Project lay summary:

Need/Gap addressed: According to The Arthritis Society's website: "the name scleroderma is derived from the Greek word skleros, which means hard, and derma, which means skin. The most characteristic feature of scleroderma is the build-up of tough scar-like fibrous tissue in the skin. The disease may affect the skin alone...or be a systemic disease that involves internal organs...Scleroderma begins with being born with the genetic potential to develop the disease. Something then triggers the immune system....to generate antibodies that attack healthy tissue.... This response produces inflammation and an overproduction of collagen " the tough fibrous protein that helps construct connective tissues, such as tendons, bones, and ligaments (and) scar tissue. This excess collagen is deposited in the skin and body organs." A cell type called the myofibroblast (a special form of fibroblast) is responsible for the overproduction of collagen and the development of tough scar tissue (a process called called fibrosis). The toughness of the scar tissue itself in turn acts on myofibroblasts to generate more collagen and scar tissue. We want to break this vicious cycle to treat scleroderma.

Research Question and Approach: The aim of our project is to identify if a protein called YAP1 (found inside the fibroblast) is responsible for generating the toughness of scar tissue. YAP1 is activated due to the acquisition of tough connective tissue and has increases levels of a gene called CCN2 that is essential for the development of scar tissue. Since drugs targeting YAP1 (e.g. Visudyne) have been in clinical use since the year 2000, they are safe to use in humans. Our project could ultimately result in the use of these drugs to treat scleroderma. In this project, we will test if:1) Visudyne can block the generation and activity of myofibroblasts, and 2) the presence of YAP1 in fibroblasts is essential for the development of skin fibrosis in our animal models of scleroderma.

Impact: We will: 1) Show if YAP1 inhibitors block the activity of myofibroblasts 2) Show if YAP1 is required for skin fibrosis 3) Provide evidence whether, in principle, YAP inhibitors could be used to treat scleroderma.

Professor, Departments of Pharmacology & Anaesthesia, Faculty of Medicine, Dalhousie University

Project Title: Sex Differences in Joint Neuropathic Pain Involve NaV1.8 Ion Channels

Annual Commitment:
Year 1: $112,200
Year 2: $119,700
​Year 3: $119,200

Keywords: neuropathic pain, osteoarthritis, electrophysiology, pain behaviour, animal models, sodium channels, joint nerves, drug discovery, gender, immunohistochemistry

Project Summary:

• Why?: Emerging evidence shows that nerves in OA joints are damaged leading to the development of neuropathic pain, while drugs like Advil© (ibuprofen) are being used which treat inflammatory pain. Therefore, a new family of drugs which manage neuropathic pain are required. A promising target for the alleviation of neuropathic pain is a sodium channel present exclusively on pain-sensing nerves. These sodium channels are responsible for the electrical activity and resultant firing of pain-sensing nerves only.
• What?: A neuronal channel called NaV1.8 has been implicated in neuropathic pain and we have previously found that blocking this channel can alleviate OA pain. Joint neuropathic pain is mediated in part by NaV1.8 channels in a sex-specific manner.
• How?: Joint nerve damage and neuropathic pain will be compared between male and female animals with knee OA. Animals will then be treated with a NaV1.8 inhibitor to see if there is a sex-specific difference in pain relief when blocking this nerve channel. Finally, we will develop a NaV1.8 antibody system which will be more effective at blocking this sodium channel and thereby prolong the analgesic window. 
• Impact?: To identify a novel treatment strategy for the alleviation of OA pain for patients who are unresponsive to the currently prescribed anti-inflammatory drugs. While this treatment would be suitable for both sexes, we predict that females will benefit more from this approach than males.

Project Lay Summary:

The number one concern of osteoarthritis (OA) patients is effective pain relief; however, this primary consumer need is often unmet. One of the reasons for this lack of effective OA pain control is that currently prescribed analgesics are treating the wrong type of pain. Emerging evidence shows that nerves in OA joints are damaged leading to the development of neuropathic pain, while drugs like Advil© (ibuprofen) are being used which treat inflammatory pain. Therefore, a new family of drugs which manage neuropathic pain are required.

A promising target for the alleviation of neuropathic pain is a sodium channel present exclusively on pain-sensing nerves. These sodium channels are responsible for the electrical activity and resultant firing of pain-sensing nerves only. Thus, targeting these neuronal channels will reduce the nerve activity associated with neuropathic pain while maintaining normal sensitivity to touch and temperature.

One such channel, called NaV1.8, has been implicated in neuropathic pain and we have previously found that blocking this channel can alleviate OA pain. A limitation of the blocker, however, is that its pain-relieving effects are short lasting. Women are more likely to suffer from OA and experience more musculoskeletal pain compared to men. The reasons for this sex distinction are unknown, but differences in neurobiology is likely to play a major part. Neuropathic pain is more common in females and this is because females are more susceptible to peripheral nerve damage.

We believe this sex difference in neuropathic pain sensitivity is linked to variations in NaV1.8 levels. Thus, we hypothesize that: Joint neuropathic pain is mediated in part by NaV1.8 channels in a sex-specific manner. Joint nerve damage and neuropathic pain will be compared between male and female animals with knee OA. Animals will then be treated with a NaV1.8 inhibitor to see if there is a sex-specific difference in pain relief when blocking this nerve channel.

Finally, we will develop a NaV1.8 antibody system which will be more effective at blocking this sodium channel and thereby prolong the analgesic window. Our proposed studies will identify a novel treatment strategy for the alleviation of OA pain for patients who are unresponsive to the currently prescribed anti-inflammatory drugs. While this treatment would be suitable for both sexes, we predict that females will benefit more from this approach than males.

Professor, Department of Pediatrics, Faculty of Medicine, University of Saskatchewan

Project title: The Biologic Basis of Co-existent Uveitis and Arthritis in Children: Towards Early Detection, Targeted Treatment, and Prevention

Annual Commitment:
Year 1: $118,374
Year 2: $119,963
​Year 3: $119,784

Keywords: antinuclear, arthritis, autoimmunity, childhood arthritis, collagen, inflammation, JIA, matrix metalloproteinase, streptocouccus, uveitis

Project Summary:

• Why?: An estimated 24,000 Canadian children live with arthritis.  One in eight children with JIA (an estimated 3,000 Canadian children) also will have uveitis, which is inflammation of the middle layer of the eyes.  The reasons why joint inflammation (arthritis) and eye inflammation (uveitis) occur together in some children are poorly understood. 
• What?: To help explain why joint and eye inflammation occur together in children.
• How?: To investigate how collagen structure is changed by certain inflammation proteins, by studying a larger group of children with arthritis and over time see if testing their blood for the same markers can be used to predict who will develop uveitis. 
• Impact?: Early recognition of uveitis in children with arthritis and prompt treatment are essential to prevent blindness. By determining the mechanisms that explain the link between arthritis and uveitis in children, we can then design more specific treatments and gain insight into possible causes of the condition.

Project Lay Summary:

An estimated 24,000 Canadian children live with arthritis.  One in eight children with JIA (an estimated 3,000 Canadian children) also will have uveitis, which is inflammation of the middle layer of the eyes. Despite intensive and often distressing therapies (for example, administration of eye drops to young children many times a day), up to one-third of affected children develop profound, permanent vision loss.  As a young adult who has endured childhood onset arthritis and uveitis stated: “Arthritis and uveitis are independently life altering; together they can have devastating consequences.  Lack of mobility or loss of sight can quickly strip the innocence of childhood.”

Uveitis is usually invisible to the patient until it causes eye damage. It can lead to permanent vision loss in one third of affected children. Early recognition of uveitis in children with arthritis and prompt treatment are essential to prevent blindness.

The reasons why joint inflammation (arthritis) and eye inflammation (uveitis) occur together in some children are poorly understood. We expect this research will help explain why  joint and eye inflammation occur together in children.  In our earlier studies of animals with joint and eye inflammation we identified collagen (a protein that is present in both the joint and the eye) as a  possible common target that is attacked by the immune system of affected children.

In this research project, we will investigate how collagen structure is changed by certain inflammation proteins. Once altered, the collagen causes an immune reaction that leads to damage in the joint and the eye.   In our prior studies in animals and in children affected with arthritis and uveitis we identified markers in the blood that are present when these two conditions occur together. Using this information we are now prepared to study a larger group of children with arthritis and over time see if testing their blood for the same markers can be used to predict who will develop uveitis.

By determining the mechanisms that explain the link between arthritis and uveitis in children, we can then design more specific treatments and gain insight into possible causes of the condition. For example, it is possible that certain infections could trigger the start of the inflammation in the joint and eye in children who have certain genetic characteristics.

This study will be conducted in childhood arthritis clinics across Canada.  We will collaborate with Canadian ophthalmologists and other researchers from the United States and the Netherlands to ensure this study is undertaken quickly and efficiently to generate results that can be promptly applied to benefit affected children. 

Assistant Professor, Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto

Project title: Personalization of osteoarthritis care using large-scale randomized evidence: network meta-analysis and methodological development

Annual Commitment:
Year 1: $100,000
Year 2: $99,926
​Year 3: $48,250

Keywords: osteoarthritis, treatment, pain, meta-analysis, randomized, evidence-based, quality of life, systematic review, knee, hip

Project summary:

• Why?: There are many treatments for osteoarthritis available, but the most effective and safest treatments are not known yet.
• What?: Our objective is to determine what treatments work best for patients with osteoarthritis.
• How?: 
  1. We will collect and critically evaluate all pertinent published trials over the last 30 years. We will employ sophisticated statistical techniques that are capable of estimating the benefits and harms of each treatment compared against each other, even if few or no head-to-head comparisons have been conducted.
  2. We will develop a statistical model that will allow us to investigate the association between treatment effects of each conservative OA treatment and personal characteristics of people living with OA. This analysis will allow us to tailor the treatment of people living with OA according to their personal characteristics.
  3. We will implement a freely available online platform to provide patients and clinicians access to the results of our analyses to facilitate shared clinical decision-making. This platform will use the characteristics of people with osteoarthritis (e.g. age, gender, disease severity) to inform users about the probability that each osteoarthritis treatment will cause more benefit than harm.
• Impact?: The present project will develop and use novel methods to produce continuously updated knowledge to optimize the treatment of millions of persons living with osteoarthritis in Canada and worldwide.

Project lay summary:

There are many treatments for osteoarthritis available, but the most effective and safest treatments are not known yet.  In this project, our objective is to determine what treatments work best for patients with osteoarthritis.

To accomplish this goal, we will collect and critically evaluate all pertinent published trials over the last 30 years. We will employ sophisticated statistical techniques that are capable of estimating the benefits and harms of each treatment compared against each other, even if few or no head-to-head comparisons have been conducted.

Furthermore, we will develop novel statistical models that enable the assessment of whether patient characteristics such as age, gender, disease severity, among others, are associated with a better response to different osteoarthritis interventions. Finally, we will implement a freely available online platform to provide patients and clinicians access to the results of our analyses to facilitate shared clinical decision-making.

This platform will use the characteristics of people with osteoarthritis (e.g. age, gender, disease severity) to inform users about the probability that each osteoarthritis treatment will cause more benefit than harm. As a whole, the present project will develop and use novel methods to produce continuously updated knowledge to optimize the treatment of millions of persons living with osteoarthritis in Canada and worldwide.

Associate Scientist, Institute for Work & Health

Project title: Work disability prevention for Millennial young adults with rheumatic disease

Annual Commitment:
Year 1: $30,772
Year 2: $49,744
​Year 3: $62,131

Keywords: employment, work disability, rheumatic disease, young adulthood, job accommodations, workplace supports, longitudinal research, productivity loss, millennial, school-to-work

Project summary:

• Why?: Despite advances in clinical care, people living with rheumatic disease (RD) continue to report trouble finding employment and staying productive at work. Because previous research focuses primarily on older adults with RD, it is unclear if Millennial young adults with RD, who are just beginning their careers, have the same needs when it comes to workplace support.
• What?: To examine the needs of Millennials with RD within the workplace.
• How?: Survey Millennial young adults with RD to learn more about their workplace support needs.
• Impact?: Results will help employers, clinicians, and policy makers develop strategies that will assist Millennials with RD transition into the world of work, and ensure that they remain employed and productive once there.

Project lay summary:

Despite advances in clinical care, people living with rheumatic disease (RD) continue to report trouble finding employment and staying productive at work. Some previous research suggests that workplace policies and practices play an important role in overcoming these challenges. The research indicates that job accommodations (e.g., modified hours), work modifications (e.g., rearranging tasks) and extended health benefits (e.g., access to drug benefits) are examples of effective strategies for helping people with RD sustain employment and remain productive.

Because previous research focuses primarily on older adults with RD, it is unclear if Millennial young adults with RD, who are just beginning their careers, have the same needs when it comes to workplace support. Our study is one of the first to examine the needs of Millennials with RD within the workplace. Millennials (born 1982-1999) make up a growing portion of the labour force but are less likely to hold permanent full-time jobs. A RD adds to the challenges faced by Millennials as they transition into employment.

We will survey Millennial young adults with RD to learn more about their workplace support needs. Our survey will also identify how characteristics of a person’s health and their working conditions impact workplace support needs, and early work experiences. Our results will help employers, clinicians, and policy makers develop strategies that will assist Millennials with RD transition into the world of work, and ensure that they remain employed and productive once there.

Scientist, Sunnybrook Research Institute, Evaluative Clinical Sciences Platform, Holland Musculoskeletal Research Program

Project title: Enhancing the Use of Rheumatology Electronic Medical Records to Evaluate and Optimize Care and Management of Arthritis

Annual Commitment:
Year 1: $99,098
Year 2: $99,910
​Year 3: $99,100

Keywords: electronic medical records, quality measure, quality indicator, quality of care, inflammatory, validation, rheumatoid arthritis, psoriatic arthritis, wait times, health services

Project summary:

• Why?: The quality of care provided to Canadians with inflammatory arthritis (IA) is not routinely monitored in Canada, nor are patient clinical outcomes.  Electronic medical records (EMRs) used by doctors capture information relevant for the day-to-day care of their patients including medical histories and the type of healthcare patients receive.
• What?:
  • Our primary research questions include:
    1. How complete are rheumatology EMRs?
    2. Can we accurately and efficiently identify patients with IA conditions from the complete practice data
    3. Is the data of sufficient quality to derive quality measures and support the measurement of quality of care and quality improvement efforts? Answering these questions will determine the feasibility and usefulness of using rheumatology EMRs for research and quality improvement purposes.
  • Secondly, we will also demonstrate the capabilities of using rheumatology EMRs to evaluate care and outcomes of IA patients. Some of the research questions that we will answer include:
    1. How long are patients waiting to see rheumatologists?
    2. Are there variations in wait times between rheumatologists?
    3. Which factors are associated with timely care?
• How?: We will securely collect EMR data from rheumatologists into a central database. We will assess the quality of this data to understand how we can use the data to measure detailed aspects of care. This will allow us to analyze the data to better inform healthcare delivery to ensure it is safe, effective and efficient and that patients achieve the best possible outcomes.
• Impact?: This project plays an essential first step to enable the measurement of quality of care to catalyze quality improvement efforts using real-world data for all patients under rheumatology care. Our results will inform continuous quality improvement including timely access to rheumatology care and treatment as well as patient outcome to ensure Canadians with IA are receiving the best possible care and achieving the best outcomes.

Project lay summary:

The quality of care provided to Canadians with inflammatory arthritis (IA) is not routinely monitored in Canada, nor are patient clinical outcomes.  Electronic medical records (EMRs) used by doctors capture information relevant for the day-to-day care of their patients including medical histories and the type of healthcare patients receive. This data can be anonymized and coded to protect patient privacy and confidentiality, and securely used for research and quality improvement activities.

We will securely collect EMR data from rheumatologists into a central database. We will assess the quality of this data to understand how we can use the data to measure detailed aspects of care. This will allow us to analyze the data to better inform healthcare delivery to ensure it is safe, effective and efficient and that patients achieve the best possible outcomes. We will do this by developing methods to evaluate quality of care using the EMR data.  We will feedback this information to rheumatologists to help drive quality improvements. We will also evaluate wait times between rheumatologists and the effect of different models of care on  wait times.

This project plays an essential first step to enable the measurement of quality of care to catalyze quality improvement efforts using real-world data for all patients under rheumatology care. Our results will inform continuous quality improvement including timely access to rheumatology care and treatment as well as patient outcome to ensure Canadians with IA are receiving the best possible care and achieving the best outcomes.

Centre de recherche, Centre hospitalier d'université de Montréal

Supervisor: Dr. Walid Mourad, Centre de recherche, Centre hospitalier d'université de Montréal

Project title: Involvement of CD154 in the atherosclerotic risk factor associated with rheumatoid arthritis

Annual Commitment:
Year 1: $20000
Year 2: $20000
Year 3: $20000

Keywords: Rheumatoid Arthritis, CD154, atherosclerosis, association, new receptors, integrins, CD154 mutants, animal model of arthritis, atherogenic mice, plasma of arthritis patients

Project Lay Summary:

Patients with Rheumatoid Arthritis show increased susceptibility to develop cardiovascular complications, as compared to the general population. Unfortunately, current drug therapies do not completely limit or prevent the development of these complications. Multiple lines of evidence now support the importance of inflammatory pathways in the pathophysiology of both complications. Our research program aims to study and understand the mechanisms by which autoimmune disease such as Rheumatoid Arthritis and heart diseases develop, and more importantly, to establish the key inflammatory contributors that link both disorders. More precisely, we intend to delineate the importance of a critical inflammatory mediator in the onset of cardiovascular complications in patients with autoimmune diseases using specific animal models, human samples and blocking agents generated in our laboratory. This project may lead to the development of novel and safe therapeutic targets for the treatment of Rheumatoid Arthritis and its cardiovascular-associated complications.

Rehabilitation Sciences Institute, University of Toronto / University Health Network

Supervisor: Dr. Zahi Touma, University Health Network

Project title: Improving the assessment and care management of everyday living limitations in adults with Systemic Lupus Erythematosus related cognitive impairments: an multi-methods examination of activities of daily living

Annual Commitment:
Year 1: $20000
Year 2: $20000

Keywords: Activities of daily living, participation, Lupus, Systemic Lupus Erythematosus, cognition dysfunction, cognitive impairment, rehabilitation, systematic review, qualitative (interview), quantitative (survey)

Project Lay Summary:

Need/gap: Over 35,000 Canadians live with the widespread effects on bodily functions and activities of daily living (ADL) associated with systemic lupus erythematosus (SLE). One significant body function area that can be affected is thinking skills, also known as cognitive functions.  Cognitive impairments (CI or issues in thinking skills) can include declines in a person’s memory, planning, and attention abilities, as well as their thinking speed.  It is estimated that up to two-thirds of people living with SLE experience CI, and these changes can have a significant effect on a person’s ADL performance.  Decreased ADL performance can decrease life satisfaction and quality of life. Currently there is no study that has examined the ADL function of people living with SLE related CI.
Research question: For people living with SLE, do people who experience associated CI have different ADL limitations than people who do not experience associated CI?

Approach to address gap: This project will use three studies to answer the research question.  The first study will review all of the available published studies that have examined ADL functioning in people with SLE. This literature includes both people with and without related CI, and reviewing it will help identify the possible ADL limitations related to SLE.  The second study will interview people with SLE and related CI regarding how changes in thinking skills has affected their daily lives and ADL functioning.  This study identifies what ADL issues might be specific to SLE related CI.  The third study will compare the self-reported ADL limitations of (1) people with SLE and CI versus (2) people with SLE and no CI.  This study will develop a survey of ADL limitations using information from the first two studies. The survey will be given to people with SLE identified as having or not having CI, and difference between the two groups’ self-reported answers will be compared.

Impact to arthritis care: The results of this study are needed to build future assessment instruments that will identify and monitor over time the ADL functioning in people with SLE and CI.  Once the areas of ADL functioning have been identified than better treatments for improving ADL function can be developed, tested, and implemented in SLE clinical practices.  This will help people stay involved in meaningful life activities, participate in their chosen life roles, and optimize quality of life.

Target audience: This information will be important for people living with SLE, caregivers, and SLE clinicians as changes in ADL functions can often be the first sign of CI. Knowing what ADLs are specifically impacted by SLE related CI can help monitor functioning over time.  Further, the results can help clinical practitioners in identifying and addressing ADL limitation areas important to people living with SLE related CI.  Further, for clinical practitioners and academic researchers, the results will provide foundational evidence and identify areas for further research in an area of that currently lacks information.

Dept. of Comparative Biology & Experimental Medicine, Faculty of Veterniary Medicine, University of Calgary

Supervisor: Dr. John Matyas, University of Calgary

Project title: Unravelling the mechanisms underlying chronic OA joint pain: A neuroimmunological focus

Annual Commitment:
Year 1: $20000
Year 2: $20000
​Year 3: $20000

Keywords: Single cell RNAseq, trauma-induced Osteoarthritis, neuroimmunology, transgenic mouse models, bioinformatics, neuropathic pain behaviour, flow and immunohistochemistry, macrophages, neuronal-macrophage co-cultures, retrograde tracing

Project Lay Summary:

Chronic joint pain, such as that experienced by those who suffer from arthritis, is a common cause of disability that is difficult to treat and is poorly understood. The symptoms of chronic pain reported by arthritis patients closely resemble those reported by patients with nerve injuries. This suggests that arthritis pain might be caused, at least in part, by injury and inflammation of the nerves in addition to damage and inflammation at the joint site. We already know that inflammation within the upstream circuitry (ie. spinal cord) of pain sensation can activate pain pathways to a point where pain originating from the joint is amplified in the spinal cord further enhancing the feeling of a painful stimulus. What we don’t know is how much this type of nervous system ‘pain’ actually contributes to a patients experience of pain. As such, we aim to further understand the mechanisms of how this type of nervous system inflammation sustains or contributes to pain sensation. The first aim of these studies is to define and quantify the molecules associated with immune cells and nerve cells that are activated during chronic joint pain. To do this we will use the latest technology to isolate thousands of individual cells, such as immune cells and nerve cells, from the pain pathway at key time points in a rodent model of chronic joint pain (ACL transection injury at 16 weeks post-injury). We will then perform an unbiased sequencing experiment where we can detect the activation profile of these cells in pain states versus the same cells in healthy conditions. We will also compare this to another pain model that is already well characterized to be driven primarily by nervous system mechanisms of pain. We believe that any common mechanisms will likely be strong therapeutic targets. Such an approach is creative because it will allow us to focus on meaningful mechanisms of pain rather than tissue specific changes that may correlate with pain but not necessarily play a role in driving pain. The second aim is to modulate these pathways with the goal of preventing or limiting the development of chronic arthritis pain. We hope to not only uncover the underlying mechanisms of chronic joint pain but also identify therapeutically relevant pathways that can be targeted to treat chronic pain in the clinic.

Dept of Psychology and Neuroscience, Faculty of Science, Dalhousie University

Supervisor: Dr. Christine Chambers, Dalhousie University 

Project title: Parental perceptions of pain and treatment adherence in juvenile idiopathic arthritis (JIA)

Annual Commitment:
Year 1: $10,500
Year 2: $10,500
​Year 3: $10,500

Keywords:Juvenile Idiopathic Arthritis, pain, treatment adherence, physical activity, medication, parent, coping, catastrophizing, attitudes, pain management

Project Lay Summary:

“Zachary lived with the pain of arthritis for nine months. Despite the fact that he knows that the medicine in the injections is making him feel better, it doesn’t make it any easier to receive the painful poke each day” [35].  Around 24,000 children across Canada live with Juvenile Idiopathic Arthritis (JIA) [1], making it one of the most common childhood chronic illnesses [2]. Pain is the most frequently reported symptom [3], caused by both the illness itself and its associated treatments. Treatment aims to manage the pain and prevent damage to the joint tissues through both medication and physical therapy [4], which when followed leads to improved outcomes [5-11]. Unfortunately, following these recommendations can be hard [6, 12-23]; many of the treatments are painful (e.g., weekly injections), or have uncomfortable side effects (e.g., nausea) [24-29]. While pain is usually something we try to avoid [61], this is not ideal when it comes to treatment-related pain. It can be difficult for a child to understand how something that hurts can be good for them, so we must rely on parents to encourage treatment adherence. Parents however, are stuck between knowing what’s best for their child, and not wanting to see their child in pain. Previous research tells us that parents behaviours and beliefs regarding their child’s experience of pain may be related to avoidance behaviours [30-32]. Now we would like to see how parents might have an effect on treatment adherence in children with JIA.

This study will look at whether parent-level factors relate to treatment adherence in children with JIA. We expect that parents who cope by avoiding things, have negative feelings about pain and medication, have little knowledge of pain-management, and score higher on fear of pain and pain catastrophizing scales will have children who are less adherent to their treatment plan.

Parents of children with JIA will be recruited via social media with the help of Cassie & Friends [33]. All families in Canada with a child under the age of 18 who has been diagnosed with JIA will be eligible. After agreeing to participate, parents will fill out online questionnaires about their child’s diagnosis and treatment, adherence, coping, self-efficacy, fear of pain, catastrophizing, and their own knowledge and attitudes regarding pain. Some of the participants will also be interviewed to better understand the barriers they face when following treatments. Analyses will determine how these parent-level factors relate to treatment adherence.

The proposed study may identify how the parent’s beliefs and knowledge around pain relate to treatment adherence, which can have significant effects on their child’s health and well-being [5-7, 34]. Once parent factors are identified, we would like to teach families ways to manage pain to see if this will reduce parental fears and anxieties. JIA is a chronic disease that has long-term effects on physical health, education, employment, mood, and relationships [71-73]. We hope that results from this study will contribute to improving treatment adherence and these long-term outcomes for children with JIA across Canada.

Dept of Pharmacology, Faculty of Medicine, Dalhousie University

Supervisor: Dr. Jason McDougall, Dalhousie University 

Project title: The Role of Proteinases in the Progression of Osteoarthritis and its associated Neuropathy

Annual Commitment:
Year 1: $10,500
Year 2: $10,500
​Year 3: $10,500

Keywords: Osteoarthritis, pain, sex-differences, neuropathic pain, serine protesases, electrophysiology, joint injury, meniscal tear, inflammation, histology

Project Lay Summary:

Osteoarthritis (OA) is the most common form of arthritis, typically affecting women at higher rates than men. OA is a painful and debilitating condition that results from the body’s failed attempt to repair damaged joint tissues. The most traditionally prescribed treatments for OA patients, non-steroidal anti-inflammatory drugs (NSAIDs), do not work for all patients and with long-term use these drugs often become less effective and can cause unwanted side effects.

Approximately 60% of people suffering from OA cite poor management of their chronic pain and this is the number one reason for patients to visit their physician. Unsatisfactory pain management is possibly due to a third of OA patients developing neuropathic pain, where the nerves within the affected joint are damaged as the disease progresses. Neuropathic pain symptoms (e.g. shooting or burning pain, “pins and needles”, numbness) are more common among women and this type of pain is resistant to traditionally used treatments. Therefore, the discovery of new drugs for treating joint neuropathic pain symptoms is necessary in combatting OA pain.

We believe that the nerves are damaged, in part, by enzymes such as serine proteinases—which are commonly found in arthritic joints. In this project, I aim to identify specific serine proteinases which may be useful targets for OA pain and then explore the analgesic ability of these serine proteinase modulators in a model of OA. The level of serine proteinases in arthritic patient’s joints will be assessed to determine if the concentration and type of proteinases present correlate with the stage of disease. Using an injury model of OA, I will study the progression of knee joint pain and nerve damage in both male and female animals, and determine if drugs targeting serine proteinases can provide pain relief once nerve damage has occurred. I will also explore whether chronic treatment with these drugs can prevent nerve damage.

This project will (1) enhance our understanding of OA pain and (2) also identify important sex-specific mechanisms underlying the difference in prevalence of OA and neuropathic pain in women and men. The results of these experiments may point towards new and sex-specific targets for drugs used to treat joint neuropathic pain.

Dept. of Physiology and Pharmacology, Schulic School of Medicine & Dentistry, Western University

Supervisor: Dr. Cheryle Séguin, Western University 

Project title: Investigating potential regulators of ectopic mineralization in a mouse model of diffuse idiopathic skeletal hyperostosis (DISH)

Annual Commitment:
Year 1: $10,500
Year 2: $10,500
​Year 3: $10,500

Keywords: Diffuse idiopathic skeletal hyperostosis, intervertebral disc, genetics, ectopic mineralization, transcriptomics, metabolomics, proteomics, systems biology, connective tissue disorders, MALDI-IMS

Project Lay Summary:

The Arthritis Society lists diffuse idiopathic skeletal hyperostosis (DISH) as the second most common form of arthritis (after osteoarthritis) with a prevalence of 15-25% of North Americans over the age of 50. However, health professionals are often unfamiliar with DISH, and consequently it is underdiagnosed and often misdiagnosed. DISH is typically diagnosed through x-ray detection of aberrant calcification of the soft connective tissues of the spine, including ligaments and intervertebral discs (IVDs). Symptoms are typically mild in the early stages of disease, including thoracic spine pain and stiffness. As such, patients are not often seen until advanced stages where the formation of ectopic calcified material affects adjacent anatomy causing dysphagia (difficulty swallowing) and/or compression of the spinal cord and adjacent nerve roots. To date, no studies have evaluated the effectiveness of any therapy in this disease, likely reflecting our poor understanding of its pathogenesis. This knowledge gap is due to limited access to human disease tissues and a lack of animal models that allow researchers to study events associated with disease onset. Consequently, apart from surgical removal of calcified tissues in severe cases, no disease-modifying treatments exist. Therefore, there is an urgent need for research studies aimed at understanding the biological mechanisms that contribute to the pathogenesis of DISH.

Our study applies technologies allowing for an unbiased screen of tissues affected by ectopic calcification to uncover the cellular and molecular underpinnings of DISH. This work is based on the use of a mouse model that our group recently reported as the first pre-clinical model of DISH (mice genetically altered to lack the gene encoding the ENT1 transport protein). This mouse model shows a remarkably reproducible temporal and spatial pattern of spine calcification resembling DISH and thus allows us to not only evaluate changes associated with the diseased state but also investigate predictors of DISH susceptibility and evaluate therapeutics. Since DISH affects the intervertebral disc, and we are experts in disc biology, we will investigate changes in this tissue to extrapolate findings to other connective tissues affected with the disease.

Our experimental strategy involves cutting edge technologies to conduct global analyses of tissues both prior to and associated with the onset of DISH-like calcification. Taking a multi-pronged approach, we aim to identify changes in: i) gene expression, ii) protein expression, and iii) metabolites associated with ectopic calcifications of spinal tissues in our mouse model of DISH. We will integrate the findings from each analysis and validate our findings in human tissues to develop a holistic view of the biology associated with DISH.

Overall, these studies aim to impact our understanding of arthritis by: i) identifying the biological pathways that lead to DISH, ii) identifying biomarkers to allow early-stage detection of DISH, ii) identify therapeutic targets to prevent or delay the onset of ectopic calcifications in DISH and associated disorders. This research integrates a collaborative, transdisciplinary team that includes biologists, technical specialists, clinicians and patient partners to ensure that in the long term, our findings impact the care of arthritis patients.

Arthritis Centres are the rheumatology division of the department of medicine in Canadian universities, including accredited pediatric rheumatology centres.

For over 30 years, the Arthritis Society has provided annual funding to Arthritis Centres across Canada. As centres of clinical expertise, research and education, their role in the Canadian health care environment is to help ensure that more Canadians with arthritis receive better care.

Current funding recipients (2017/18) of $15,000 for a term of one year are:

• McMaster University
• SickKids Hospital, University of Toronto
• Research Institute of MUHC, McGill University
• Montreal Children’s Hospital, McGill University
• University of Manitoba
• University of Calgary
• Dalhousie University
• CHU de Quebec, Université Laval
• University of Saskatchewan
• University of Alberta

Arthritis Centre grants support Centres that align with one or more of the following goals:

• Increasing the number of Rheumatologists
• Improving Models of Care
• Supporting Arthritis Research

Every year, the field of rheumatology changes with new knowledge collected by research scientists from across Canada and around the world. Translation of this knowledge is important for the development of evidence-based rheumatology practice. Since allied health professionals play a large role in rheumatology, it is important that they be able to provide evidence for their roles in the field and demonstrate the positive impact that they have on the care of people with inflammatory arthritic disease. The AHPA encourages its members to contribute knowledge to the field by holding an annual research grant competition and recognizing their research efforts at the Canadian Rheumatology Association’s and AHPA’s Annual Scientific Meeting. An award of $5000 will be honored for the best research proposal submitted by an AHPA member. A list of recipients of this award can be found here.